Drug Dictionary


mFOLFIRINOX Found Superior to Gemzar for Treatment Surgically Resected Pancreatic Cancer (06-19-2018)

The results of a recently presented clinical study at the American Society of Clinical Oncology meetings last week suggest that more aggressive chemotherapy treatment improves outcomes compared to single agent Gemzar (gemcitabine) chemotherapy which has... Continue Reading

abemaciclib (01-17-2018)

Generic Name: abemaciclib Trade Name: Verzenio For which conditions is this drug approved? Verzenio is indicated for use: In combination with fulvestrant in women with hormone receptor (HR)-positive, HER2-negative advanced or metastatic breast cancer... Continue Reading

Verzenio™ (01-17-2018)

Generic Name: abemaciclib Trade Name: Verzenio For which conditions is this drug approved? Verzenio is indicated for use: In combination with fulvestrant in women with hormone receptor (HR)-positive, HER2-negative advanced or metastatic breast cancer... Continue Reading

tisagenlecleucel (01-17-2018)

Generic Name: tisagenlecleucel Trade Name: KYMRIAH For which conditions is this drug approved? KYMRIAH is indicated for the treatment of patients up to 25 years of age with B-cell precursor acute lymphoblastic leukemia (ALL) that is refractory or in second... Continue Reading

KYMRIAH™ (01-17-2018)

Generic Name: tisagenlecleucel Trade Name: KYMRIAH For which conditions is this drug approved? KYMRIAH is indicated for the treatment of patients up to 25 years of age with B-cell precursor acute lymphoblastic leukemia (ALL) that is refractory or in second... Continue Reading

YESCARTA™ (01-17-2018)

Generic Name: axicabtagene ciloleucel Trade Name: YESCARTA For which conditions is this drug approved? YESCARTA is indicated for the treatment of adult patients with relapsed or refractory large B-cell lymphomas after two or more lines of systemic treatment.... Continue Reading

axicabtagene ciloleucel (01-17-2018)

Generic Name: axicabtagene ciloleucel Trade Name: YESCARTA For which conditions is this drug approved? YESCARTA is indicated for the treatment of adult patients with relapsed or refractory large B-cell lymphomas after two or more lines of systemic treatment.... Continue Reading

acalabrutinib (01-17-2018)

Generic Name: acalabrutinib Trade Name: CALQUENCE® For which conditions is this drug approved? CALQUENCE is indicated for the treatment of adults with mantle cell lymphoma (MCL) who have received at least one prior therapy. What is the mechanism of action? CALQUENCE... Continue Reading

CALQUENCE® (01-17-2018)

Generic Name: acalabrutinib Trade Name: CALQUENCE® For which conditions is this drug approved? CALQUENCE is indicated for the treatment of adults with mantle cell lymphoma (MCL) who have received at least one prior therapy. What is the mechanism of action? CALQUENCE... Continue Reading

IDHIFA® (01-17-2018)

Generic Name: enasidenib Trade Name: IDHIFA® For which conditions is this drug approved? IDHIFA is indicated for the treatment of adults with relapsed or refractory acute myeloid leukemia (AML) with an isocitrate dehydrogenase-2 (IDH2) mutation as detected... Continue Reading

Next Page »